Welcome > Support > Âü°íÀÚ·á  
 
 
E
 
±Ûº¸±â
¼º¸í ÆijªÁø     (Date : 2016-07-13 10:22:54)
Á¦¸ñ [³í¹®] [2015]IDH Mutation Analysis in Ewing Sarcoma Family Tumors.
³»¿ë


J Pathol Transl Med. 2015 May;49(3):257-61. doi: 10.4132/jptm.2015.04.14. Epub 2015 May 15.

IDH Mutation Analysis in Ewing Sarcoma Family Tumors.

Na KY1Noh BJ2Sung JY3Kim YW3Santini Araujo E4Park YK3.

Author information

Abstract

BACKGROUND:

Isocitrate dehydrogenase (IDH) catalyzes the oxidative decarboxylation of isocitrate to yield α-ketoglutarate (α-KG) with production of reduced nicotinamide adenine dinucleotide (NADH). Dysfunctional IDH leads to reduced production of α-KG and NADH and increased production of 2-hydroxyglutarate, an oncometabolite. This results in increased oxidative damage and stabilization of hypoxia-inducible factor α, causing cells to be prone to tumorigenesis.

METHODS:

This study investigated IDH mutations in 61 Ewing sarcoma family tumors (ESFTs), using a pentose nucleic acid clamping method and direct sequencing.

RESULTS:

We identified four cases of ESFTs harboring IDH mutations. The number of IDH1 and IDH2 mutations was equal and the subtype of IDH mutations was variable. Clinicopathologic analysis according to IDH mutation status did not reveal significant results.

CONCLUSIONS:

This study is the first to report IDH mutations in ESFTs. The results indicate that ESFTs can harbor IDH mutations in previously known hot-spot regions, although their incidence is rare. Further validation with a larger case-based study would establish more reliable and significant data on prevalence rate and the biological significance of IDH mutations in ESFTs.

KEYWORDS:

Isocitrate dehydrogenase; PNA clamping; Sarcoma, Ewing


 

 ¹øÈ£   Á¦¸ñ ÀÛ¼ºÀÚ ÆÄÀÏ Á¶È¸
   49           [³í¹®] [2016]Comparison of EGFR .. ÆijªÁø 28869
¢º           [³í¹®] [2015]IDH Mutation Analys.. ÆijªÁø 65535
   47           [³í¹®] [2015]Low frequency of KR.. ÆijªÁø 29206
   46           [³í¹®] [2015]Simultaneous genoty.. ÆijªÁø 6063
   45           [³í¹®] [2014]Simultaneous diagno.. ÆijªÁø 20969
   44           [³í¹®] [2014]KRAS Mutation Detec.. ÆijªÁø 8119
   43           [³í¹®] [2013]Detection of EGFR m.. ÆijªÁø 1171
   42           [³í¹®] [2013]Detection and compa.. ÆijªÁø 5811
   41           [³í¹®] [2013]Detection of BRAF V.. ÆijªÁø 6093
   40           [³í¹®] [2013]Comparison of Direc.. ÆijªÁø 25281
   39           [³í¹®] [Microarray]Peptide nucle.. ÆijªÁø 14317
   38           [³í¹®] [Clamp]Rapid and Sensitiv.. ÆijªÁø 22238
   37           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] EGFR µ¹¿¬º¯.. ÆijªÁø 3383
   36           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] Development .. ÆijªÁø 14153
   35           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] JHDM3A modul.. ÆijªÁø 1162
   34           [³í¹®] [PNA Chip vs DNA Chip ÀÓ»ó.. ÆijªÁø 4023
   33           [³í¹®] [ÆijªÁø ³í¹®¹ßÇ¥] PNA-mediated Re.. ÆijªÁø 8818
   32           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡.. ÆijªÁø 14473
   31           [³í¹®] [ÆijªÁø ³í¹® ¹ßÇ¥] PNA-Based Anti.. ÆijªÁø 1167
   30           [³í¹®] [ÆijªÁø ³í¹®¹ßÇ¥]Peptide nucleic .. ÆijªÁø 3889
 

< 1 2 3 >